People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy -; proton beam therapy or intensity modulated radiation therapy (IMRT) -; ...
The Commission on Radiotherapy and Theranostics follows up on the 2015 Lancet Oncology Commission on expanding global radiotherapy access. Despite progress over the past decade, a disparity in ...
The Lancet Oncology Commission on Radiotherapy and Theranostics report highlights the importance of implementing cost-effective approaches in low- and middle-income countries, where access to ...